Keratoacanthoma - Keratoacantoma
☆ I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
Tipiciúil Keratoacantoma (Keratoacanthoma)
References
Is meall craicinn é Keratoacanthoma (KA) go minic a bhfuil aithne air mar gheall ar a fhás tapa agus a chumas dul siar ar ais leis féin. Tarlaíonn sé go hiondúil i fir aosta, cothrom-craiceann a bhfuil stair damáiste gréine acu. Cé gur gnáthchóireáil é baint máinliachta ag baint úsáide as máistreacht nó máinliacht mhicreagrafach Mohs, tá roghanna teiripe éagsúla eile ar fáil.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Is meall de ghrád íseal é Keratoacanthoma (KA) a thosaíonn i faireoga áirithe sa chraiceann agus a bhreathnaíonn cosúil le squamous cell carcinoma (SCC) faoi mhicreascóp. Tá díospóireacht leanúnach ar siúl faoi cibé ar cheart KA a rangú mar chineál SCC ionrach.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Is é Cutaneous squamous cell carcinoma (cSCC) an dara cineál ailse is coitianta i ndaoine, go háirithe i measc daoine scothaosta. Úsáidtear máinliacht de ghnáth chun cSCC a chóireáil, ach i gcás roinnt othar nach féidir leo máinliacht a fháil nó nach roghnaíonn, is féidir roghanna eile cosúil le cóireálacha infhéitheacha a mheas. Baineadh úsáid as cóireálacha infhéitheacha traidisiúnta (methotrexate or 5-fluorouracil) , ach tá taighde leanúnach ar siúl ar chur chuige nua mar imdhíonteiripe infhéitheach agus víriteiripe oncolytic. Anseo, féachfaimid ar chóireálacha intralesional éagsúla le haghaidh cSCC, ó mhodhanna clasaiceacha go straitéisí ceannródaíocha.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Faoin micreascóp, is cosúil go dlúth le keratoacantoma (keratoacanthoma) carcinoma cille squamous. Cé go n-aicmíonn roinnt paiteolaithe keratoacantoma (keratoacanthoma) mar aonán ar leith agus ní mar aonán urchóideach, déanann thart ar 6% de na keratoacantoma (keratoacanthoma) cliniciúla agus histeolaíocha dul ar aghaidh chuig ailsí cille squamous ionracha agus ionsaitheach.
○ Diagnóis agus Cóireáil
#Dermoscopy
#Skin biopsy